Fred Alt

Director of the Program in Cellular & Molecular Medicine at Boston Children’s Hospital

Fred Alt

Fred Alt

Director of the Program in Cellular & Molecular Medicine at Boston Children’s Hospital

Biography

Dr. Frederick W. Alt is the director of the Program in Cellular and Molecular Medicine at Boston Children’s Hospital, a professor of Genetics at Harvard Medical School, and an investigator of the Howard Hughes Medical Institute.

Dr. Alt, who was first funded by the Cancer Research Institute as a postdoctoral fellow, has made fundamental contributions to our understanding of B cell development and function, and the mechanisms underlying B cell lymphomas.

His honors include election to the National Academy of Sciences, and awards including the 2009 William B. Coley Award for Distinguished Research in Basic Immunology and the 2015 Szent-Györgyi Prize for Progress in Cancer Research. In recognition of his accomplishments, CRI also started the Frederick W. Alt Award, which honors a former CRI postdoctoral fellow who has achieved outstanding success that has impacted immunology. In addition to being a member of CRI’s Scientific Advisory Council, Dr. Alt serves on the Postdoctoral Fellowship Review Committee.

Cancer is a complex and terrible disease, but with each new discovery we are making it less mysterious, more understandable, and ultimately less deadly. We are making progress.

Overview
RelSci Relationships

3590

Number of Boards

8

Relationships
RelSci Relationships are individuals Fred Alt likely has professional access to. A relationship does not necessarily indicate a personal connection.

President & Chief Executive Officer at Dana-Farber Cancer Institute, Inc.

Relationship likelihood: Strong

Founder at Agios Pharmaceuticals, Inc.

Relationship likelihood: Strong

Senior Investigator, Program in Cellular & Molecular Medicine at Boston Children’s Hospital

Relationship likelihood: Strong

Founder at Jounce Therapeutics, Inc.

Relationship likelihood: Strong

Scientific Founder at Tmunity Therapeutics, Inc.

Relationship likelihood: Strong

Edward Mallinckrodt Junior Professor-Immunopathology at Harvard University - Harvard Medical School

Relationship likelihood: Strong

Chief Scientific Officer at ISA Pharmaceuticals BV

Relationship likelihood: Strong

Professor at University of Connecticut

Relationship likelihood: Strong

Senior Vice President, Experimental Medicine at Dana-Farber Cancer Institute, Inc.

Relationship likelihood: Strong

Co-Founder at Revolution Medicines, Inc.

Relationship likelihood: Strong

Paths to Fred Alt
Potential Connections via
Relationship Science
You
Fred Alt
Director of the Program in Cellular & Molecular Medicine at Boston Children’s Hospital
Career History
Director of the Program in Cellular & Molecular Medicine
Current

Children's Hospital Corp. provides health care services that includes acupuncture, cardiac anesthesia, pediatric cataract, andrology program, atopic dermatits center, augmentative communication program, exercise physiology, endodontics, and many more. The company was founded in 1869 and is headquartered in Boston, MA.

Professor of Genetics
Current

Harvard Medical School (HMS) is the graduate medical school of Harvard University. It is located in the Longwood Medical Area of the Mission Hill neighborhood of Boston, Massachusetts.The school was founded by John Warren on September 19, 1782, with Benjamin Waterhouse, and Aaron Dexter.

Boards & Committees
Member, Scientific Advisory Board
Current

Cellectis SA is a biopharmaceutical company, which engages in the research and development of genome engineering technology. The company operates through the following business segments: Therapeutics and Plants. The Therapeutics segment is focused on the development of products in the field of immune-oncology and of novel products outside immuno-oncology to treat other human diseases. The Plants segment focuses on applying its gene-editing technologies to develop new generation plant products in the field of agricultural biotechnology through its own efforts or through alliances with other companies in the agricultural market. Its therapeutic products are still in the preclinical stage which is developed for various kinds of tumors. Cellectis was founded by David J. Sourdive and André Choulika on February 20, 1999 and is headquartered in Paris, France.

This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by Fred Alt. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of Fred Alt's profile does not indicate a business or promotional relationship of any kind between RelSci and Fred Alt.